Mobocertinib

Unassigned

New Medicines

Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation - second-line

Information

New molecular entity
Takeda
Takeda

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

A tyrosine kinase inhibitor of activating exon 20 mutations in EGFR and HER2
There were 46,403 new cases of lung cancer diagnosed in the UK in 2014. NSCLC accounts for 85% of cases of lung cancer. The NSCLCs are often grouped together when treatment is being considered [1].
Non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutation - second-line
Oral